B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
Media
Links
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J., March 2, 2021 – B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation, announce the launch of a global co-marketing agreement to promote the use of CytoSorb® with B. Braun’s latest OMNI® continuous blood purification platform and OMNIset® Plus bloodline set (set version 3.0 or higher).
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
The CytoSorb adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream./ - CYTOSORBENTS
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI Continuous Blood Purification Platform with CytoSorb Joint marketing of CytoSorb with B. Braun s newest OMNI blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J., March 2, 2021 / News Aktuell- B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its C